Reduction of Parenteral Nutrition in Children with Short Bowel Syndrome Treated with Teduglutide: Experience from the Czech Republic

Short bowel syndrome (SBS) results from a severe reduction in intestinal absorptive capacity, rendering it insufficient to meet the body's nutritional requirements. Teduglutide represents a novel therapeutic approach for patients with SBS. This study aims to share our experiences and outcomes of Teduglutide treatment in children with SBS, focusing on the development of their anthropometric parameters.This study included all pediatric SBS patients in the Czech Republic receiving home parenteral nutrition (PN) who began Teduglutide treatment from May 2019 to June 2024.We analyzed the changes in volume and caloric content of PN and anthropometric parameters for each patient.All 10 patients showed a reduction in PN volume and caloric content during Teduglutide treatment with a mean value 67%+/- 29. There was also a notable decrease in the caloric content of PN, although this did not always correlate with the volume reduction, the mean value was 52.3%+/- 40.6. Despite the reduced reliance on PN, there was a mean improvement in weight and height among the patients. Gastrointestinal complications were the most common side effects observed.Our findings confirm the positive impact of Teduglutide on intestinal absorption in pediatric SBS patients. They also validate its safety and efficacy in this population. Despite the reduction in PN, improvements in weight were evident across the entire patient cohort.